Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myc proto-oncogene protein (commonly called c-Myc or MYC) is a basic helix-loop-helix leucine zipper transcription factor encoded by the MYC gene. It is a key regulator of cell growth, proliferation, and metabolism, and controls expression of a wide array of genes by binding specific DNA sequences. As a proto-oncogene, MYC is frequently dysregulated in cancer, where its constitutive expression promotes uncontrolled cellular proliferation and tumorigenesis. Because of its central role in cancer, MYC is a highly studied but challenging therapeutic target, with most drug strategies focused on indirect inhibition via mRNA targeting or protein-protein interaction disruption[1][5].
Inhibitors attempt to block MYC expression, promote MYC degradation, disrupt protein-protein interactions, or block translation of MYC mRNA[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myc proto-oncogene protein (c-Myc (or MYC)).